-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 28th, Baiji Shenzhou officially launched a global strategic partnership with U.S. biopharmaceutical company Xinji in the field of oncology in Beijing, marking the official entry into the operational phase of the innovative cooperation model between the two sides.
understood that the cooperation involved a total of 1,393 million U.S. dollars, a new record for the transfer of the rights and interests of domestic pharmaceutical companies.
announced the cooperation on July 5, 2017, the two sides completed the relevant transactions on August 31. Based on the terms of the contract, Baiji Shenzhou took over the company's commercial team in China and assumed the sales functions of the new base's approved products in China - ABRAXANE injections for advanced breast cancer with yew alcohol (albumin binding), rejuminants for the treatment of multiple myeloma (lynadamine) and Vidasha (injection azasides) for the treatment of myeloma syndrome, as well as commercial responsibility for the development of the product CC-12.
Xinji has obtained exclusive authorization for the development and commercialization of BGB-A317 solid tumor adaptation in many countries and regions outside the United States, Europe, Japan, and Asia, while Baiji Shinjuju retains the rights to BGB-A317 for solid tumors in Asia, excluding Japan, as well as global rights in the field of hematoma and internal drug combinations.
of the $1,393 million transaction-related funds related to the transfer of single-species interests of domestic pharmaceutical companies, The state is eligible for an additional $980 million in development, pharmaceutical and sales milestone payments and future sales royalties for BGB-A317, in addition to a total of $413 million in licensed advances and equity investments from Xinji.
At the same time, at the launch ceremony, Baiji Shenzhou officially announced for the first time to increase BGB-A317 investment in the domestic market, that is, the rapid spread of China's common cancer species (lung, stomach, liver, esophageal cancer) registered clinical trials
